<p>Eton Pharmaceuticals（ETON）正在準備於 2025 年 5 月 13 日發佈其季度財報。在公告之前，投資者應注意以下幾點。</p>
<p>分析師預計 Eton Pharmaceuticals 的 <strong>每股收益</strong>（EPS）為 0.03 美元。</p>
<p>Eton Pharmaceuticals 的公告備受期待，投資者希望能獲得超出預期的消息以及對下個季度的積極指引。</p>
<p>值得新投資者注意的是，指引可能是股價波動的關鍵因素。</p>
<h3>過去的收益表現</h3>
<p>該公司在上個季度的 EPS 未達到預期，差額為 0.00 美元，導致次日股價上漲 1.36%。</p>
<p>以下是 Eton Pharmaceuticals 的過去表現及其導致的價格變化：</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1747058590_0.png/query-YXV0bz13ZWJwJmRwcj0yJm9wdGltaXplPW1lZGl1bSZ3aWR0aD0xOTIw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1747058590_0.png/query-YXV0bz13ZWJwJmRwcj0yJm9wdGltaXplPW1lZGl1bSZ3aWR0aD0xOTIw"/></p>
<h3>Eton Pharmaceuticals 股票表現</h3>
<p>截至 5 月 9 日，Eton Pharmaceuticals 的股票交易價格為 16.79 美元。在過去 52 周內，股票上漲了 360.74%。鑑於這些回報通常是積極的，長期股東在此次財報發佈前可能持樂觀態度。</p>
<h3>分析師對 Eton Pharmaceuticals 的看法</h3>
<p>對於投資者而言，瞭解市場情緒和行業預期至關重要。本分析提供了關於 Eton Pharmaceuticals 的最新見解。</p>
<p>Eton Pharmaceuticals 的共識評級為買入，基於 3 位分析師的評級。平均一年期目標價為 27.67 美元，意味着潛在的 64.8% 上漲空間。</p>
<h3>同業評級分析</h3>
<p>在此比較中，我們探討了 Tilray Brands、Zevra Therapeutics 和 EyePoint Pharmaceuticals 這三家行業知名公司的分析師評級和平均一年期目標價，提供了對其相對錶現預期和市場定位的見解。</p>
<ul>
<li>分析師目前對 Tilray Brands 持中性態度，平均一年期目標價為 1.0 美元，暗示潛在的 94.04% 下跌空間。</li>
<li>分析師目前對 Zevra Therapeutics 持買入態度，平均一年期目標價為 22.0 美元，暗示潛在的 31.03% 上漲空間。</li>
<li>分析師目前對 EyePoint Pharmaceuticals 持買入態度，平均一年期目標價為 27.33 美元，暗示潛在的 62.78% 上漲空間。</li>
</ul>
<h3>快照：同行分析</h3>
<p>同行分析摘要提供了 Tilray Brands、Zevra Therapeutics 和 EyePoint Pharmaceuticals 的關鍵指標的詳細審查，提供了對它們在行業內的地位、市場定位和相對錶現的有價值見解。</p>
<p>關鍵要點：</p>
<p>Eton Pharmaceuticals 在同行中在收入增長和毛利潤方面排名第一。然而，在股本回報率方面排名最後。</p>
<h3>揭示 Eton Pharmaceuticals 背後的故事</h3>
<p>Eton Pharmaceuticals Inc 是一家總部位於美國的專業製藥公司。該公司致力於開發和商業化藥品，以滿足未滿足的患者需求。它擁有四種商業化的罕見疾病產品，分別是用於治療腎上腺皮質功能不全的 Alkindi Sprinkle；用於治療高氨血癥的 Carglumic Acid；用於治療同型半胱氨酸尿症的 Betaine Anhydrous；以及用於治療遺傳性酪氨酸血癥 1 型（HT-1）的 Nitisinone。該公司還有三種處於後期開發階段的產品候選者：ET-400、ET-600 和 ZENEO 氫化可的松自動注射器。</p>
<h3>解讀 Eton Pharmaceuticals 的財務故事</h3>
<p><strong>市值視角：</strong> 該公司的市值低於行業平均水平，表明其相較於同行規模較小。這種定位可能受到感知增長潛力或運營規模等因素的影響。</p>
<p><strong>收入增長：</strong> Eton Pharmaceuticals 在過去三個月表現積極。截至 2024 年 12 月 31 日，該公司實現了約 <strong>59.26%</strong> 的穩健收入增長率。這表明公司的頂線收益顯著增加。與同行相比，該公司的收入增長落後於行業同行。在醫療保健行業中，其增長率低於同行的平均水平。</p>
<p><strong>淨利潤率：</strong> Eton Pharmaceuticals 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率為 <strong>-5.13%</strong>，顯示出強大的盈利能力和有效的成本管理。</p>
<p><strong>股本回報率（ROE）：</strong> Eton Pharmaceuticals 的 ROE 超過行業標準，突顯了公司的卓越財務表現。其 ROE 為 <strong>-2.96%</strong>，有效利用了股東權益資本。</p>
<p><strong>資產回報率（ROA）：</strong> Eton Pharmaceuticals 的 ROA 超越行業基準，達到 <strong>-1.07%</strong>。這表明其資產管理高效，財務健康狀況良好。</p>
<p><strong>債務管理：</strong> Eton Pharmaceuticals 的債務與股本比率低於行業平均水平。其比率為 <strong>1.22</strong>，表明公司對債務融資的依賴較小，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
<p><strong>要查看 Eton Pharmaceuticals 的所有財報發佈，請訪問我們網站上的財報日曆。</strong></p>
<p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>

ETON

<p>Eton Pharmaceuticals 將於 2025 年 5 月 13 日公佈季度財報，分析師預測每股收益（EPS）為 0.03 美元。該公司過去一年股價上漲了 360.74%，目前交易價格為 16.79 美元。分析師對 Eton 的評級為 “買入”，一年目標價為 27.67 美元，意味着潛在上漲空間為 64.8%。Eton 在同行中在收入增長和毛利潤方面排名較高，但在股本回報率方面排名較低。該公司的淨利潤率為-5.13%，債務與股本比率為 1.22，表明其債務管理有效</p>

<p>Eton Pharmaceuticals ETON is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals（ETON）正在準備於 2025 年 5 月 13 日發佈其季度財報。在公告之前，投資者應注意以下幾點。</p>
</div><p>Analysts expect Eton Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $0.03.</p>
<div class="lb-trans"><p>分析師預計 Eton Pharmaceuticals 的 <strong>每股收益</strong>（EPS）為 0.03 美元。</p>
</div><p>The announcement from Eton Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals 的公告備受期待，投資者希望能獲得超出預期的消息以及對下個季度的積極指引。</p>
</div><p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<div class="lb-trans"><p>值得新投資者注意的是，指引可能是股價波動的關鍵因素。</p>
</div><h3>Past Earnings Performance</h3>
<div class="lb-trans"><h3>過去的收益表現</h3>
</div><p>The company's EPS missed by $0.00 in the last quarter, leading to a 1.36% increase in the share price on the following day.</p>
<div class="lb-trans"><p>該公司在上個季度的 EPS 未達到預期，差額為 0.00 美元，導致次日股價上漲 1.36%。</p>
</div><p>Here's a look at Eton Pharmaceuticals's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是 Eton Pharmaceuticals 的過去表現及其導致的價格變化：</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1747058590_0.png/query-YXV0bz13ZWJwJmRwcj0yJm9wdGltaXplPW1lZGl1bSZ3aWR0aD0xOTIw" alt="" original-src="https://www.benzinga.com/files/images/story/2025/1747058590_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920"/></p>
<h3>Performance of Eton Pharmaceuticals Shares</h3>
<div class="lb-trans"><h3>Eton Pharmaceuticals 股票表現</h3>
</div><p>Shares of Eton Pharmaceuticals were trading at $16.79 as of May 09. Over the last 52-week period, shares are up 360.74%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.</p>
<div class="lb-trans"><p>截至 5 月 9 日，Eton Pharmaceuticals 的股票交易價格為 16.79 美元。在過去 52 周內，股票上漲了 360.74%。鑑於這些回報通常是積極的，長期股東在此次財報發佈前可能持樂觀態度。</p>
</div><h3>Analysts' Perspectives on Eton Pharmaceuticals</h3>
<div class="lb-trans"><h3>分析師對 Eton Pharmaceuticals 的看法</h3>
</div><p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Eton Pharmaceuticals.</p>
<div class="lb-trans"><p>對於投資者而言，瞭解市場情緒和行業預期至關重要。本分析提供了關於 Eton Pharmaceuticals 的最新見解。</p>
</div><p>The consensus rating for Eton Pharmaceuticals is Buy, derived from 3 analyst ratings. An average one-year price target of $27.67 implies a potential 64.8% upside.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals 的共識評級為買入，基於 3 位分析師的評級。平均一年期目標價為 27.67 美元，意味着潛在的 64.8% 上漲空間。</p>
</div><h3>Analyzing Ratings Among Peers</h3>
<div class="lb-trans"><h3>同業評級分析</h3>
</div><p>In this comparison, we explore the analyst ratings and average 1-year price targets of Tilray Brands, Zevra Therapeutics and EyePoint Pharmaceuticals, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<div class="lb-trans"><p>在此比較中，我們探討了 Tilray Brands、Zevra Therapeutics 和 EyePoint Pharmaceuticals 這三家行業知名公司的分析師評級和平均一年期目標價，提供了對其相對錶現預期和市場定位的見解。</p>
</div><ul>
<li>Analysts currently favor an Neutral trajectory for Tilray Brands, with an average 1-year price target of $1.0, suggesting a potential 94.04% downside.</li>
<li>Analysts currently favor an Buy trajectory for Zevra Therapeutics, with an average 1-year price target of $22.0, suggesting a potential 31.03% upside.</li>
<li>Analysts currently favor an Buy trajectory for EyePoint Pharmaceuticals, with an average 1-year price target of $27.33, suggesting a potential 62.78% upside.</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師目前對 Tilray Brands 持中性態度，平均一年期目標價為 1.0 美元，暗示潛在的 94.04% 下跌空間。</li>
<li>分析師目前對 Zevra Therapeutics 持買入態度，平均一年期目標價為 22.0 美元，暗示潛在的 31.03% 上漲空間。</li>
<li>分析師目前對 EyePoint Pharmaceuticals 持買入態度，平均一年期目標價為 27.33 美元，暗示潛在的 62.78% 上漲空間。</li>
</ul>
</div><h3>Snapshot: Peer Analysis</h3>
<div class="lb-trans"><h3>快照：同行分析</h3>
</div><p>The peer analysis summary offers a detailed examination of key metrics for Tilray Brands, Zevra Therapeutics and EyePoint Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<div class="lb-trans"><p>同行分析摘要提供了 Tilray Brands、Zevra Therapeutics 和 EyePoint Pharmaceuticals 的關鍵指標的詳細審查，提供了對它們在行業內的地位、市場定位和相對錶現的有價值見解。</p>
</div><p>Key Takeaway:</p>
<div class="lb-trans"><p>關鍵要點：</p>
</div><p>Eton Pharmaceuticals ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals 在同行中在收入增長和毛利潤方面排名第一。然而，在股本回報率方面排名最後。</p>
</div><h3>Unveiling the Story Behind Eton Pharmaceuticals</h3>
<div class="lb-trans"><h3>揭示 Eton Pharmaceuticals 背後的故事</h3>
</div><p>Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals Inc 是一家總部位於美國的專業製藥公司。該公司致力於開發和商業化藥品，以滿足未滿足的患者需求。它擁有四種商業化的罕見疾病產品，分別是用於治療腎上腺皮質功能不全的 Alkindi Sprinkle；用於治療高氨血癥的 Carglumic Acid；用於治療同型半胱氨酸尿症的 Betaine Anhydrous；以及用於治療遺傳性酪氨酸血癥 1 型（HT-1）的 Nitisinone。該公司還有三種處於後期開發階段的產品候選者：ET-400、ET-600 和 ZENEO 氫化可的松自動注射器。</p>
</div><h3>Unraveling the Financial Story of Eton Pharmaceuticals</h3>
<div class="lb-trans"><h3>解讀 Eton Pharmaceuticals 的財務故事</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值視角：</strong> 該公司的市值低於行業平均水平，表明其相較於同行規模較小。這種定位可能受到感知增長潛力或運營規模等因素的影響。</p>
</div><p><strong>Revenue Growth:</strong> Eton Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>59.26%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> Eton Pharmaceuticals 在過去三個月表現積極。截至 2024 年 12 月 31 日，該公司實現了約 <strong>59.26%</strong> 的穩健收入增長率。這表明公司的頂線收益顯著增加。與同行相比，該公司的收入增長落後於行業同行。在醫療保健行業中，其增長率低於同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Eton Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-5.13%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Eton Pharmaceuticals 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率為 <strong>-5.13%</strong>，顯示出強大的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> Eton Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-2.96%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Eton Pharmaceuticals 的 ROE 超過行業標準，突顯了公司的卓越財務表現。其 ROE 為 <strong>-2.96%</strong>，有效利用了股東權益資本。</p>
</div><p><strong>Return on Assets (ROA):</strong> Eton Pharmaceuticals's ROA excels beyond industry benchmarks, reaching <strong>-1.07%</strong>. This signifies efficient management of assets and strong financial health.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Eton Pharmaceuticals 的 ROA 超越行業基準，達到 <strong>-1.07%</strong>。這表明其資產管理高效，財務健康狀況良好。</p>
</div><p><strong>Debt Management:</strong> Eton Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of <strong>1.22</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Eton Pharmaceuticals 的債務與股本比率低於行業平均水平。其比率為 <strong>1.22</strong>，表明公司對債務融資的依賴較小，保持了債務與股本之間更健康的平衡，這對投資者來説是一個積極的信號。</p>
</div><p><strong>To track all earnings releases for Eton Pharmaceuticals visit their earnings calendar on our site.</strong></p>
<div class="lb-trans"><p><strong>要查看 Eton Pharmaceuticals 的所有財報發佈，請訪問我們網站上的財報日曆。</strong></p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>
</div>

展望：Eton Pharmaceuticals 的盈利預測